Logo image of SXTP

60 DEGREES PHARMA INC (SXTP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SXTP - US83006G4010 - Common Stock

0.8299 USD
+0.01 (+1.19%)
Last: 12/16/2025, 8:00:01 PM
0.83 USD
+0 (+0.01%)
After Hours: 12/16/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SXTP. SXTP was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SXTP have multiple concerns. While showing a medium growth rate, SXTP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SXTP had negative earnings in the past year.
SXTP had a negative operating cash flow in the past year.
SXTP had negative earnings in each of the past 5 years.
SXTP had a negative operating cash flow in each of the past 5 years.
SXTP Yearly Net Income VS EBIT VS OCF VS FCFSXTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

SXTP has a Return On Assets of -126.70%. This is amonst the worse of the industry: SXTP underperforms 83.25% of its industry peers.
SXTP has a worse Return On Equity (-191.31%) than 73.82% of its industry peers.
Industry RankSector Rank
ROA -126.7%
ROE -191.31%
ROIC N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SXTP Yearly ROA, ROE, ROICSXTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

SXTP's Gross Margin of 42.47% is fine compared to the rest of the industry. SXTP outperforms 61.78% of its industry peers.
SXTP's Gross Margin has declined in the last couple of years.
SXTP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
SXTP Yearly Profit, Operating, Gross MarginsSXTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

3

2. Health

2.1 Basic Checks

SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
SXTP has more shares outstanding than it did 1 year ago.
The debt/assets ratio for SXTP is higher compared to a year ago.
SXTP Yearly Shares OutstandingSXTP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SXTP Yearly Total Debt VS Total AssetsSXTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

SXTP has an Altman-Z score of -11.77. This is a bad value and indicates that SXTP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SXTP (-11.77) is worse than 76.96% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that SXTP is not too dependend on debt financing.
SXTP has a Debt to Equity ratio (0.03) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -11.77
ROIC/WACCN/A
WACC9.38%
SXTP Yearly LT Debt VS Equity VS FCFSXTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 2.87 indicates that SXTP has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.87, SXTP is in line with its industry, outperforming 50.79% of the companies in the same industry.
A Quick Ratio of 2.63 indicates that SXTP has no problem at all paying its short term obligations.
SXTP has a Quick ratio of 2.63. This is comparable to the rest of the industry: SXTP outperforms 53.40% of its industry peers.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.63
SXTP Yearly Current Assets VS Current LiabilitesSXTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

5

3. Growth

3.1 Past

SXTP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.25%, which is quite impressive.
SXTP shows a strong growth in Revenue. In the last year, the Revenue has grown by 192.74%.
The Revenue for SXTP have been decreasing by -52.49% on average. This is quite bad
EPS 1Y (TTM)61.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.81%
Revenue 1Y (TTM)192.74%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%291.53%

3.2 Future

The Earnings Per Share is expected to grow by 25.73% on average over the next years. This is a very strong growth
SXTP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.16% yearly.
EPS Next Y91.22%
EPS Next 2Y39.78%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue Next Year164.27%
Revenue Next 2Y81.47%
Revenue Next 3Y82.46%
Revenue Next 5Y48.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SXTP Yearly Revenue VS EstimatesSXTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2M 4M 6M
SXTP Yearly EPS VS EstimatesSXTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SXTP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SXTP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTP Price Earnings VS Forward Price EarningsSXTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTP Per share dataSXTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as SXTP's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.78%
EPS Next 3Y25.73%

More info and screens

0

5. Dividend

5.1 Amount

SXTP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

60 DEGREES PHARMA INC

NASDAQ:SXTP (12/16/2025, 8:00:01 PM)

After market: 0.83 +0 (+0.01%)

0.8299

+0.01 (+1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/dmh
Earnings (Next)N/A N/A
Inst Owners4.94%
Inst Owner Change179.48%
Ins Owners1.16%
Ins Owner Change1.21%
Market Cap3.51M
Revenue(TTM)1.35M
Net Income(TTM)-8.48M
Analysts82.5
Price Target4.49 (441.03%)
Short Float %1.3%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.43%
Min EPS beat(2)-27.66%
Max EPS beat(2)46.52%
EPS beat(4)1
Avg EPS beat(4)-61.15%
Min EPS beat(4)-247.17%
Max EPS beat(4)46.52%
EPS beat(8)2
Avg EPS beat(8)-34.36%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.91%
Min Revenue beat(2)0.28%
Max Revenue beat(2)29.55%
Revenue beat(4)2
Avg Revenue beat(4)-0.75%
Min Revenue beat(4)-29.6%
Max Revenue beat(4)29.55%
Revenue beat(8)2
Avg Revenue beat(8)-18.2%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-37.14%
PT rev (3m)-37.14%
EPS NQ rev (1m)49.11%
EPS NQ rev (3m)20.83%
EPS NY rev (1m)-53.02%
EPS NY rev (3m)-53.02%
Revenue NQ rev (1m)33.75%
Revenue NQ rev (3m)30.65%
Revenue NY rev (1m)35.76%
Revenue NY rev (3m)35.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.59
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)-17.67
EYN/A
EPS(NY)-1.76
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.61
OCFYN/A
SpS0.32
BVpS1.05
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -126.7%
ROE -191.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.47%
FCFM N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
F-Score3
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 112.77%
Cap/Sales 6.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.63
Altman-Z -11.77
F-Score3
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)258.14%
Cap/Depr(5y)228.76%
Cap/Sales(3y)28.01%
Cap/Sales(5y)17.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.81%
EPS Next Y91.22%
EPS Next 2Y39.78%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue 1Y (TTM)192.74%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%291.53%
Revenue Next Year164.27%
Revenue Next 2Y81.47%
Revenue Next 3Y82.46%
Revenue Next 5Y48.16%
EBIT growth 1Y16.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-47.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.49%
OCF growth 3YN/A
OCF growth 5YN/A

60 DEGREES PHARMA INC / SXTP FAQ

What is the fundamental rating for SXTP stock?

ChartMill assigns a fundamental rating of 2 / 10 to SXTP.


Can you provide the valuation status for 60 DEGREES PHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to 60 DEGREES PHARMA INC (SXTP). This can be considered as Overvalued.


What is the profitability of SXTP stock?

60 DEGREES PHARMA INC (SXTP) has a profitability rating of 1 / 10.


What is the expected EPS growth for 60 DEGREES PHARMA INC (SXTP) stock?

The Earnings per Share (EPS) of 60 DEGREES PHARMA INC (SXTP) is expected to grow by 91.22% in the next year.